Notably, off-label tenecteplase had already become the preferred thrombolytic for acute ischemic stroke before the expanded ...

Biotech-focused investment firm Frazier Life Sciences launched Callio Therapeutics, a cancer treatment startup with ...

Genentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug ...

In 2023, Roche said it was removing TNKase for stroke from its phase 3 programmes after a readout of the TIMELESS trial, but ...

Genentech has had the lone medicine on the market for the acute treatment of stroke. | Over nearly the last three decades, ...

Genentech announced that the U.S. Food and Drug Administration has approved TNKase, a thrombolytic or clot-dissolving agent, for the treatment ...

Genentech, part of the Roche (ROG SIX) group, has received a new approval from the US Food and Drug Administration for TNKase ...

European life sciences venture capital company Sofinnova Partners has raised €1.2 billion ($1.27 billion) in new funding that ...

Genentech, a member of the Roche Group, announced that the FDA has approved the company’s TNKase (tenecteplase) thrombolytic ...

Just nine weeks after UnitedHealthcare CEO Brian Thompson was murdered on a weekday morning on a busy street, the luminaries ...

Underpinning UC Berkeley’s world-renowned laboratories, research and numerous Nobel Prize winners lies a uniquely precise ...